TESTING & RESULTS
BE PART OF THE FUTURE OF PARKINSON’S
COMPLETED USER TESTING
Initial Proof of Concept, Movement Tests
Our first trial round involved 13 people with Parkinson’s across a variety of ages and stages of Parkinson’s. We had them carry out various movement tests including walking, moving objects and using tools with and without the device. All tests were carried out during each person’s best-medicated state.
CUE1 Device with Stappone Insole Sensor Technology
We partnered with Austrian company Stappone to analyse the effect of CUE1 on gait in people with Parkinson’s using their pressure-sensitive insole. MDS-UPDRS assessments were compared with objective features of gait (peak heel pressure, double support time and gait symmetry).
MDS-UPDRS, Timed Up & Go 3m, Tapping & Usability Feedback
In this round of testing, we wanted to further explore the utility of CUE1, and so we listened to the recommendations of Parkinson’s clinicians, who advised us to record the MDS-UPDRS Section III score. This is widely regarded as the gold standard for Parkinsonian symptoms.
TAKE PART IN PARKINSON'S CLINICAL TRIALS
Our clinical team are preparing for our upcoming clinical trials for people with Parkinson’s to further evaluate the efficacy of CUE1 for symptoms of Parkinson’s. However, with the current situation with the COVID-19 pandemic, our trials will be delayed until we are absolutely sure that it is safe for everyone to get involved in the trial.
If you would like to learn more, take a part in our future clinical research trials or participate in user testing, please do get in touch with us.
Our phase one clinical trials will be based in the UK but the information will be available for the worldwide Parkinson’s community.
Working closely with people with Parkinson’s has been a priority throughout the development of CUE1 and we plan to continue these efforts through formal clinical trials carried out in partnership with the NHS.
Make a real difference and be part of the future of non-invasive treatment for people with Parkinson’s.